Chest
Original Research: COPDNurse-Conducted Smoking Cessation in Patients With COPD Using Nicotine Sublingual Tablets and Behavioral Support
Section snippets
Patients
Patients with COPD previously diagnosed by a physician were recruited from seven lung clinics using newspaper advertisements in some centers. The first patient was enrolled in February 2002, and the last patient was enrolled in June 2004. Patients enrolled were aged ≥ 18 years; were smoking one or cigarettes a day; had persistent airway obstruction with FEV1/FVC < 70% and FEV1 < 90% of predicted normal value; and were willing to follow the study protocol. Lung function testing was performed
Baseline Characteristics and Study Completion
A total of 370 COPD patients were enrolled in the four treatment arms (Table 1). Overall, the average age was 61.0 years and mean FEV1 was 55.8% of predicted. In terms of COPD severity, 9% of subjects had FEV1 > 80% of predicted, 53% had FEV1 50 to 80% of predicted, 30% had FEV1 30 to 50% of predicted, and 8% had FEV1 < 30% of predicted. At baseline, the study population smoked a mean of 19.6 cigarettes per day (mean, 42.7 pack-years). Fewer than one tenth of those enrolled smoked < 7
Efficacy of NRT for Smoking Cessation in COPD Patients
This is the first randomized, controlled trial to demonstrate the efficacy of NRT for smoking cessation in patients with all stages of COPD and also in smokers who consume < 15 cigarettes per day. The main finding was more than a doubling of sustained abstinence rates with nicotine sublingual tablets vs placebo in a group of COPD patients with mild, moderate, and severe reduction in lung function. The actual 1-year quit rate of 14% with the nicotine sublingual tablet is in the same range as
CONCLUSION
The results demonstrate that the use of sublingual nicotine tablets in conjunction with a nursing-run cessation program results in higher rates of smoking cessation compared to placebo. The quit rate achieved in our study was comparable to that achieved with NRT in “healthy smokers.” NRT should be offered to patients with COPD as part of a smoking cessation program.
At this time, data are insufficient to draw conclusions about the relative efficacy of different forms of NRT in COPD patients, but
ACKNOWLEDGMENT
We thank the nurses in all seven centers for their assistance in this study.
REFERENCES (36)
- et al.
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial
Lancet
(2001) - et al.
Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD
Chest
(2001) - et al.
The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review
Respir Med
(2004) NICE. Chronic obstructive pulmonary disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care
Thorax
(2004)- et al.
Treating tobacco use and dependence: clinical practice guideline.
(2000) - et al.
Antidepressants for smoking cessation
Cochrane Database Syst Rev
(2004) - et al.
Nicotine replacement therapy for smoking cessation
Cochrane Database Syst Rev
(2004) British Thoracic Society. Comparison of four methods of smoking cessation withdrawal in patients with smoking related diseases
BMJ
(1983)- et al.
Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease
Arch Intern Med
(2005)
Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support
Thorax
A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation
Addiction
Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study
Thorax
Smoking reduction, smoking cessation and mortality: a 16-year follow-up of 19,732 men and women from the Copenhagen Centre for Prospective Population Studies
Am J Epidemiol
Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety
BMJ
Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up
Addiction
Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung function Tests, European Community for Steel and Coal; Official Statement of the European Respiratory Society
Eur Respir J
ATS/ERS Task Force: standards for the diagnosis and treatment of patients with COPD; a summary of the ATS/ERS position paper
Eur Respir J
Cited by (114)
Effects of different interventions on smoking cessation in chronic obstructive pulmonary disease patients: A systematic review and network meta-analysis
2022, International Journal of Nursing StudiesOverview of Current Management of COPD
2021, Encyclopedia of Respiratory Medicine, Second EditionSmoking cessation in asthmatic patients and its impact
2021, Revue des Maladies RespiratoiresSmoking Cessation/Vaccinations
2020, Clinics in Chest MedicineOutcomes and predictive factors for successful smoking cessation therapy in COPD patients with nicotine dependence
2020, Respiratory Investigation
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestjournal.org/misc/reprints.shtml)
Other recruiting pulmonary departments are Helsingør Sygehus; Odense University Hospital; Århus Kommunehospital; Bispebjerg Hospital; Nykøbing Falster Sygehus; Frederiksberg Hospital.
The Danish Medical Research Council provided the major grant for this study ($375,000; No. 9900732 kg/mp). Pfizer Consumer Healthcare, Sweden, supplied the study drugs used in the trial and provided grant support ($25,000).
Dr. Mikkelsen and Ms. Bremann have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Dr. Tønnesen has served on advisory boards regarding smoking cessation agents, has participated in clinical trials with smoking cessation drugs, has received honorary for scientific talks and travel grants from Pfizer, GlaxoSmithKline, and Sanofi Aventis.